Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

Fineline Cube Apr 30, 2026
Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations

Fineline Cube Apr 30, 2026
Company Deals

HQ Pharma and Shanghai Pharmaceuticals Expand Collaboration for Global Market Access

Fineline Cube Feb 26, 2025

China’s HQ Pharma (Shanghai) Co., Ltd has entered into a new collaboration agreement with Shanghai...

Company Deals

Green Valley and Vazyme Team Up on Alzheimer’s Disease Initiatives

Fineline Cube Feb 26, 2025

China-based Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and Vazyme Biotech Co., Ltd (SHA: 688105) have...

Company Drug

Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review

Fineline Cube Feb 26, 2025

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...

Company Deals

CARsgen Therapeutics and Zhuhai SB Xinchuang Invest in UCARsgen for Allogeneic CAR-T Therapies

Fineline Cube Feb 26, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has entered into an agreement with an investment...

Company Drug

Eli Lilly Launches New Zepbound Doses with Lower Prices for Self-Pay Patients

Fineline Cube Feb 26, 2025

Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg...

Company Drug

Suzhou Ribo Life Science’s RBD2080 siRNA Drug Receives Australian Clinical Trial Approval

Fineline Cube Feb 26, 2025

China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...

Company

MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study

Fineline Cube Feb 26, 2025

Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace,...

Company Deals

Eli Lilly Acquires Organovo’s FXR Program for Inflammatory Bowel Disease

Fineline Cube Feb 26, 2025

US-based Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical-stage biotech focused on inflammatory bowel disease (IBD),...

Company Medical Device

Acotec Scientific’s Vericor Catheter Wins NMPA Approval for Peripheral Vascular Surgery

Fineline Cube Feb 25, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its peripheral disposable support catheter Vericor...

Drug

CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study

Fineline Cube Feb 25, 2025

China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...

Company Drug

Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US

Fineline Cube Feb 25, 2025

Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...

Company

CDE Includes Chiral Tech’s Cerdelga Generic in Rare Disease Care Plan

Fineline Cube Feb 25, 2025

China’s Center for Drug Evaluation (CDE) announced the inclusion of Beijing Chiral Tech’s generic version...

Company Medical Device

Medtronic’s BrainSense Adaptive DBS Wins FDA Approval for Parkinson’s Treatment

Fineline Cube Feb 25, 2025

US-Irish medical device giant Medtronic (NYSE: MDT) announced that the US Food and Drug Administration...

Legal / IP

SMPA Suspends Indobufen Procurement After Patent Infringement Verdict

Fineline Cube Feb 25, 2025

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) announced the suspension of procurement for indobufen, manufactured by...

Company Drug

Xellsmart’s iPSC Therapy XS-228 Receives FDA Approval for ALS Study

Fineline Cube Feb 25, 2025

Suzhou-based stem-cell startup Xellsmart announced that the U.S. FDA has approved its regulatory study of...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for OSA Treatment

Fineline Cube Feb 25, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its HDM1005, a long-acting GLP-1/GIP receptor...

Company Drug

Pfizer’s Hympavzi (Marstacimab) Launched in China’s Boao Lecheng Pilot Zone for Hemophilia

Fineline Cube Feb 25, 2025

Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s...

Company Deals

Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors

Fineline Cube Feb 25, 2025

Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...

Company

Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M

Fineline Cube Feb 25, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues...

Company Drug

Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer

Fineline Cube Feb 25, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...

Posts pagination

1 … 200 201 202 … 659

Recent updates

  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
  • 3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal
  • Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline
  • Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial
  • Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength

Company

3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Company Drug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.